AU2011202771A1 - Oxazolidinone-quinolone hybrid antibiotics - Google Patents

Abstract

The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and are effective against a variety of multi-drug resistant bacteria.

Description

Pool Section 29 Regulation 3.2(2) AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Application Number: Lodged: Invention Title: Oxazolidinone-quinolone hybrid antibiotics The following statement is a full description of this invention, including the best method of performing it known to us: P111AHAU/0710 1 Oxazolidinone-quinolone hybrid antibiotics The present invention describes new compounds in which the pharmacophores of quinolone and oxazolidinone are 5 linked together through a linker that is stable under physiological conditions and a pharmaceutical antibacterial composition containing these compounds. These dual action compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including Gram 10 positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as Gram negative bacteria such as Moraxella catarrhalis and Haemophilus influenzae and anaerobic organisms such as bacteroides app. and Clostridia spp. species and acid-fast 15 organism such as Mycobacterium tuberculosis, Mycobacterium avium spp. Oxazolidinone-quinolone hybrid antibiotics have already been described (WO02059116, W003002560, W003031443, 20 W003032962) . The major drawback of the compounds known in the state of the art is the poor water solubility, which makes the development of a formulation difficult. The present invention provides new compounds of 25 formula (I), that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria R2 R Y / A (CH2) R A-Q N \0

(CH

2 )m F N OH

(R

2 wherein A is an alkylene group, an alkenylene group, an alkynylene group, a heteroalkylene group, a 5 cycloalkylene group, a heterocycloalkylene group, an ary ene group or a heteroarylene group all of which groups may be substituted; Q iE CR 4 or N (especially CR 4 ); 10 X in CR 7 or N; Y in CR 6 or N; 15 n is 1, 2 or 3; m is 1, 2 or 3; R. is H, F, Cl, Br, I, OH, NH 2 , an alkyl group or a 20 heteroalkyl group;

R'

2 .s H, F or Cl; R3 is H, an alkyl group, an alkenyl group, an alkynyl 25 group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkylaryl group or a heteroarylalky: group; all of which groups may be substituted with one, two or more halogen atoms like F or Cl or amino groups. 30

R

4 ia hydroxy, a group of formula OP0 3 R% or O03R 0 or a heteroalkyl group carrying at least one OH, NN2, S0 3

R

0 , PO3R2 or COOH group or an ester of a naturally 3 occurring amino acid or a derivative thereof., wherein the groups R 9 independently of each other are H, alkyl, cycloalkyl, aryl or aralkyl and wherein R" is H, alkyl, cycloalkyl,aryl or aralkyl; 5 Rs is selected from following groups: R RK-r N RKN 0 0 0 R 8R8- R8%N 0-N RK

R

6 is H, F, Cl or OMe; 10

R

7 is H, F, Cl, OH, NH 2 , a substituted or unsubstituted alkyl group or a substituted or unsubstituted hetero alkyl group, or 15 R 3 and R 7 can be linked via an alkylene, an alkenylene or a heteroalkylene group or be a part of a cycloalkylene or heterocycloalkylene group; in case R 3 is no H and R' is no H, F, OH, NH2 or Cl; and 20 R 8 is a C1..g heteroalkyl, a heteroarylalkyl, a hetero alkylaryl or a heteroalkylheteroaryl group; or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof. 25 It should be appreciated that certain compounds of formula (I) or (II) as mentioned in this description may have tautomeric forms from which only one might be 4 specifically mentioned or depicted in this description, different geometrical isomers (which are usually denoted as cis/tranE isomers or more generally as (E) and (Z) Lsomers) or different optical isomers as a result of one or nore 5 chiral carbon atoms (which are usually nomenclature under the Cahn Ingold-Prelog or R/S system). Further, some compounds may display polymorphism. All these tautoneric forms, geometrical or optical isomers (as well as racemates and diastereomers) and polymorphous forms are included in 10 the inve tion. The term alkyl refers to a saturated straight or branched chain alkyl group, preferably containing from one to ten, preferably one to six carbon atoms, for example 15 methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec butyl, tart-butyl, n-pentyl, iso-pentyl, n-hexyl, 2,2-. dimethyloutyl, n-octyl or n-pentyl groups. Any alkyl group as defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, NH 2 , OH, SE or NO 2 . 20 The terms alkenyl and alkynyl refer to an unsaturated straight or branched chain alkyl group (having one, two or more double and/or triple bonds, an alkenyl preferably having cne or two double bonds and an alkynyl preferably 25 having cne or two triple bonds), preferably contai ing'two to ten, preferably two to six carbon atoms for example: ethenyl (vinyl), propenyl (allyl), iso-propenyl, n penteny , butenyl, isoprenyl or hexa-2-enyl; ethyn l, propyny: or butynyl groups. Any alkenyl or alkynyl group as 30 defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, NH 2 , OH, S1 or NO 2

-

5 The term heteroalkyl refers to an alkyl, alkenyl or alkynyl group as defined herein where one or more carbon atoms are replaced by an oxygen, nitrogen, phosphorous or sulphur atom, for example an alkoxy group such as methoxy, 5 ethoxy, propoxy, iso-propoxy, butoxy or tert.-butoxy, an alkoxyalkyl group such as methoxymethyl, ethoxymethyl, 1 methoxyethyl, 1-ethoxyethyl, 2-methoxyethyl or 2 ethoxyethyl, an alkylamino group such as methylamino, ethylamino, propylamino, isopropylamino, dimethylamino or 10 diethylamino, an alkylthio group such as methylthio, ethylthio or isopropylthio or a cyano group. It may also refer to one of the above groups containing a keto group. The term heteroalkyl furthermore refers to a group derived from a carboxylic acid or carboxylic acid amide such as 15 acetyl, propionyl, acetyloxy, propionyloxy, acetylamino or propionylamino, a carboxyalkyl group such as carboxymethyl, carboxyethyl or carboxypropyl, a carboxyalkyl ester, an alkylthiocarboxyamino group, an alkoxyimino group, an alkylaminothiocarboxyamino group or an alkoxycarbonylamino 20 group. Any heteroalkyl group as defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, NH 2 , OH, SH or NO 2 . The term cycloalkyl refers to a saturated or partially 25 unsaturated (having one, two or more double and/or triple bonds) cyclic group with one, two or more rings, having three to 14 carbon ring-atoms, preferably from five or six to ten carbon ring-atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetralin, 30 cyclopentenyl or cyclohex-2-enyl groups. Any cycloalkyl group as defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, OH, NH 2 , SH,

N

3 , NO 2 , alkyl groups such as methyl or ethyl, heteroalkyl 6 groups such as methoxy, methylamino, dimethylamino or cyanide. The term heterocycloalkyl refers to a cycloalky1 group 5 as definEd herein where one, two or more carbon ring-atoms are replaced by one, two or more oxygen, nitrogen, phosphorous or sulphur atoms or S(0)1- 2 groups for example piperidino, morpholino or piperazino groups. 10 The term aryl refers to an aromatic cyclic group with one, two or more rings, having five to 14 carbon ring-atoms preferab y from five or six to ten carbon ring-atoms, for example phenyl or naphthyl groups. Any aryl group as defined herein may be substituted with one, two or more 15 substituents, for example F, Cl, Br, I, OH, NH 2 , SH N 3 ,

NO

2 , alkyl groups such as methyl or ethyl, heteroalkyl groups such as methoxy, methylamino, dimethylamino or cyanide. 20 The term heteroaryl refers to an aryl group as defined herein were one, two or more ring-carbon atoms are replaced by an oxygen, nitrogen, boron, phosphorouE or sulphur atom, for example pyridyl, imidazolyl, pyrazolyl, quinolinyl, isoquinolinyl, pyrrolyl, oxazolyl, isoxazolyl, 25 thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, tetrazolyl, pyrazinyl, pyrimidinyl and pyridazinyl groups. The term aralkyl (or arylalkyl or alkylaryl) refers to 30 groups that comprise both aryl as well as alkyl and/or cycloalkyl groups.

7 The term heteroarylalkyl (or heteroalkylaryl or heteroalkylheteroaryl etc.) refers to an aralkyl group as defined herein where one, two, three or more carbon atoms are replaced by one, two, three or more oxygen, nitrogen, 5 phosphorous or sulphur atoms or S(0)1-2 groups. Any alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl or heteroaryl alkyl groups as defined herein may be substituted with one 10 or more halogen atoms, NH2, SH, NO 2 or OH groups or unsubstituted alkyl, heteroalkyl, aryl, aralkyl, aralkyl oxy, heteroaryl, cycloalkyl or heterocycloalkyl groups as defined herein. 15 The term "optionally substituted" or "substituted" refer to groups wherein one or more hydrogen atoms may be replaced by a halogen atom, a NH 2 , SH, NO 2 or OH group or by an unsubstituted alkyl, heteroalkyl, aryl, aralkyl, aralkyloxy, heteroaryl, cycloalkyl or heterocycloalkyl 20 group as defined herein. Preferred and/or advantageous embodiments of the invention are subject-matter of the subclaims. 25 Preferred are compounds of Formula (I), wherein R' is H. Further preferred are compounds of Formula (I), wherein R2 is F or H. 30 Moreover preferred are compounds of Formula (I), wherein R' is an ethyl, a 2-propyl, a C 3

-C

6 cycloalkyl (i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), a 8 phenyl ox a pyridyl group. All these groups may be substituted with one, two, three or more fluorine a oms or amino grCups. 5 Moreover preferred are compounds of Formula (I wherein R, is a cyclopropyl group. Further preferred are compounds of Formula (I), wherein I' and R 3 together form a bridge of the formula -0 10 CH 2 -N(Me)- or -C-CH 2 -CH(Me)-. Herein, the preferred stereochemistry at the chiral center is the one giving the (S) configuration in the final compound. Moreover preferred are compounds of formula (I), 15 wherein :4 is hydroxy or a group of formula OSO 3 H, OP0 3

H

2 ,

OCH

2 0PO 3 2, OCOCH 2

CH

2 COOH or an ester of a naturally occurring amino acid or a derivative thereof (i.e. a group of formula -OCOCHR'NH 2 or a derivative like an ester, amide or alkylamine thereof, wherein R' is the side chair. of a 20 naturally occurring amino acid like aspartic acid, glutaric acid, lysine, etc; e.g. dimethyl aminoglycine

OCOCH

2 N( H 3

)

2 ). Fuxther..preferred are compounds of Formula (I: 25 wherein Ra is a group of the formula -CH2NHCOCH=CHAcyl,

-CH

2 OHet roaryl (especially -oxa-3-oxazol),

-CH

2 NHSD2Me,

-CH

2 NHCO Me, -CH 2 NHCOMe, -CH 2 1'CS2Me, -CH 2 NHCSMe, -CH2NHCSNH 2 ,

-CH

2 NHCSJMe or -NHCOMe; especially -CH2NHCSMe or -C 2 NHCOMe. 30 Especially preferred are compounds of Formula (I), wherein R5 has the following structure: 9 '0N N H o-4 Moreover preferred are compounds of Formula (I), wherein R' is H, F, Cl or a methoxy group that may be 5 substituted by one, two or three fluorine atoms. Further preferred are compounds of formula (I), wherein X is N or CH. 10 Moreover preferred are compounds of Formula (I), wherein Y is CH or N. Further preferred are compounds of Formula (I), wherein A is C16 alkylene, C2-6 alkenylene, C2-6 alkynylene, 15 C1- heteroalkylene, cyclopropylene, epoxide, aziridine, thioepoxide, lactame or lactone, all of which groups may be subsitituted. Moreover preferred are compounds of formula (I), 20 wherein A is a group of Formula -O-B-, wherein B is a C14 alkylene group, a C2-4 alkenylene group, a C2..4 alkynylene group or a C-4 heteroalkylene group, all of which groups may be substituted by one, two or more hydroxy or amino groups. 25 Especially preferred are compounds of formula (I), wherein A is a group of formula -CH 2

CH

2 -, -OCH 2 -, -OCH 2

CH

2 -,

-SCH

2 -, -SCH 2

CH

2 -, -CH=CH-, -C=C-, -CH(OH)CH(OH)- or CH (NH 2 ) CH(OH) -.

10 Especially preferred are compounds of formula I), wherein E is CH 2 or CH2CH2. Especially preferred are compounds of formula (II) 5 F 0 R

(CH

2 )\ A N \/0 C N o (CH2)m X HN '40 /N OH F (11) Ra wherein the residues are defined as above. In a preferred embodiment B is CH2 or CH 2

CH

2 ; X is CH, N or C-OMe 10 and R 3 is cyclopropyl or X is CR7 and R' and R 2 together form a bridge of the formula -O-CH 2 -CH (Me)-, wherein the preferred stereochemistry at the chiral center is the one giving the (S) configuration in the final compound, n is 1, 2 or 3, M is 1, 2 or 3 and R 4 is hydroxy or a group of 15 formula SO3H, OPO 3

H

2 , OCH20P03H 2 , OCOCH2CH2COOH or an ester of a naturally occurring amino acid or a derivative thereof. Mor over preferred are the mono, di or tri sodium 20 salts (most preferred the mono sodium salts) of compounds of formula (I) or (1I) or mixtures thereof. Especially preferred are the mono, di or tri sodium salts (most preferred the mono sodium salts) of compounds of formula (I) or ( I), wherein R 4 is OP03H 2 or OSOH or mixtures 25 thereof. Especially preferred is the sodium salt of a compound of formula (II) wherein R 3 is a cyclopropyl group, X is CH or N, n is 2, m is 2, R 4 is OP0 3 1H 2 and B is C112.

11 The present invention also relates to pharma cologically acceptable salts, or solvates and hydrates, respectively, and to compositions and formulations of 5 compounds of Formula (I) or (II). The present invention describes procedures to produce pharmaceutically useful agents, which contain these compounds, as well as the use of these compounds for the production of pharmaceutically useful agents. 10 The pharmaceutical compositions according to the present invention contain at least one compound of Formula (I) or (II) as the active agent and optionally carriers and/or diluents and/or adjuvants. Optionally the 15 pharmaceutical compositions according to the present invention may also contain additional known antibiotics. Examples of pharmacologically acceptable salts of sufficiently basic compounds of Formula (I) or (II) are 20 salts of physiologically acceptable mineral acids like hydrochloric, hydrobromic, sulfuric and phosphoric acid; or salts of organic acids like methanesulfonic, p toluenesulfonic, lactic, acetic, trifluoroacetic, citric, succinic, fumaric, maleic and salicylic acid. Further, a 25 sufficiently acidic compound of Formula (I) or (II) may form alkali or earth alkaline metal salts, for example sodium, potassium, lithium, calcium or magnesium salts; ammonium salts; or organic base salts, for example methylamine, dimethylamine, trimethylamine, triethylamine, 30 ethylenediamine, ethanolamine, choline hydroxide, meglumin, piperidine, morpholine, tris-(2-hydroxyethyl)amine, lysine or arginine salts. Compounds of Formula (I) or (II) may be solvated, especially hydrated. The hydratisation can occur 12 during the process of production or as a consequence of the hygroscoIic nature of the initially water free compounds of Formula (I) or (II) . The compounds of Formula (I) or (II) may cont in asymmetric C-atoms and may be present either as 5 achiral compounds, mixtures of diastereomers, mixtures of enantiomErs or as optically pure compounds. The present invention also relates to pro-drugs which are composed of a compound of Formula (I) or (II) and at 10 least one pharmacologically acceptable protective group which wi 1 be cleaved off under physiological conditions, such as an alkoxy-, aralkyloxy-, acyl-, S03H, P0 3

H

2 , acyloxymethyl group (e.g. pivaloyloxymethyl), an 2-alkyl-, 2-aryl- or 2-aralkyl-oxycarbonyl-2-alkylidene ethyl group 15 or an acrloxy group as defined herein, e.g. ethoxy, benzyloxr, acetyl or acetyloxy. Especially preferred d are prodrugs of the hydroxy group of a compound of formula (I) or (II) wherein R 4 is OH. 20 As mentioned above, therapeutically useful agents that contain ompounds of Formula (I) or (II), their solvates, salts or formulations are also comprised in the scope of the present invention. In general, compounds of Formula (I) or (II) will be administered by using the known and 25 acceptable modes khown in the art, either alone or in combination with any other therapeutic agent. Such therapeutically useful agents can be administered by one of the following routes: oral, e.g. as tablets, dragees, coated tablets, pills, semisolids, soft or hard capsules, 30 for example soft and hard gelatine capsules, aqueous or oily so utions, emulsions, suspensions or syrups, parents al including intravenous, intramuscular and subcutareous injection, e.g. as an injectable solution or 13 suspension, rectal as suppositories, by inhalation or insufflation, e.g. as a powder formulation, as microcrystals or as a spray (e.g. liquid aerosol), trans dermal, for example via an transdermal delivery system 5 (TDS) such as a plaster containing the active ingredient or intranasal. For the production of such tablets, pills, semisolids, coated tablets, dragees and hard, e.g. gelatin, capsules the therapeutically useful product may be mixed with pharmaceutically inert, inorganic or organic 10 excipients as are e.g. lactose, sucrose, glucose, gelatin, malt, silica gel, starch or derivatives thereof, talc, stearinic acid or their salts, dried skim milk, and the like. For the production of soft capsules one may use excipients as are e.g. vegetable, petroleum, animal or 15 synthetic oils, wax, fat, polyols. For the production of liquid solutions, emulsions or suspensions or syrups one may use as excipients e.g. water, alcohols, aqueous saline, aqueous dextrose, polyols, glycerin, lipids, phospholipids, cyclodextrins, vegetable, petroleum, animal or synthetic 20 oils. Especially preferred are lipids and more preferred are phospholipids (preferred of natural origin; especially preferred with a particle size between 300 to 350 nm) preferred in phosphate buffered saline (pH = 7 to 8, preferred 7.4). For suppositories one may use excipients as 25 are e.g. vegetable, petroleum, animal or synthetic oils, wax, fat and polyols. For aerosol formulations one may use compressed gases suitable for this purpose, as are e.g. oxygen, nitrogen and carbon dioxide. The pharmaceutically useful agents may also contain additives for conservation, 30 stabilisation, e.g. UV stabilizers, emulsifiers, sweetener, aromatisers, salts to change the osmotic pressure, buffers, coating additives and antioxidants.

14 A daily dosage per patient of about 1mg to abo t 4000mg es specially about 50mg to 3 g is usual with t ose of ordinary skill in the art appreciating that the dos ge will depend also upon the age, conditions of the mammals, and 5 the kind of diseases being treated or prevented. The daily dosage can be administrated in a single dose or can be divided cver several doses. An average single dose of about 50mg, 10Cmg, 250mg, 500mg, 1000mg and 2000mg can be contemplated. 10 The compounds of formula (I) and (II) can be synthesized according to the following reaction scheme: 2N F 5 Hfl02 N F cOPr N NN FF O B (CH(C(CH2 n N N N F N OH R' 0H\ N

A

1 B N-z0 0 .~ 0 N6 MsO (H N (CO,',nNNH 0

(OH

2 OH 0 N (j)

CH

15 reaction conditions: step 1: CH 2 Cl 2 , KOH (50%), 3h, rt; 97%. step 2: H 2 , Pt/C, 20h, rt; followed by Z-Cl (Cbz-Cl), acetone/water, NaHCO 3 , 12h, rt, 98%. step 3: n-BuLi, -60-C, 24h, 80%. step 4: 5 MsCl, triethylamine, CH2Cl 2 ; 100%. step 5: NaN3 in DMF, 900C, cat. Bu 4 NI, Sh, 90%. step 6: H 2 , Pd(OH) 2 , THF, MeOH, 24h, followed by AcOH, Ac 2 0, rt, 2h, 70%. step 7: DMF, NaH, 701C, 12h, 75%. step 8: H2, Pd(OH) 2 , MeOH, THF, 24h, RT, 100%. step 9: N-Methylpyrrolidinone, 1-Cyclopropyl-7 10 chloro-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthydrin-3 carboxylic acid (commercially available), TMS-CI, Hnnig Base or K2CO3, 800C, 5h, 80%.

16 Examples Example 1: 7- (4-{4- [(5S)-5-(Acetylamino-methyl)-2-o o 5 oxazolidin-3-yll -2-fluoro-phenoxymethyl} -4-hydroxy piperidir-1-yl) -l-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro [1, Binap thyridine-3-carboxylic acid F 0 00 o N O N' 0 H 10 Step 1; 4-Benzyloxy-3-fluoro-phenyl)-carbamic acid benzyl ester: A solution of 34.99 1-benzyloxy-2-fluoro-4-nitro-be zene (WO03064413) (MW:247.28, 141mmol) and 340mg platinium 5% on activated carbon in 350ml ethyl acetate was stirred under 15 hydrogen at rt, and normal pressure. The reaction was monitored by HPLC and was complete after twenty hours. The catalyst was filtered over a glass fiber filter, and the filtrate evaporated under reduced pressure to dryness. The oily residue was dissolved in 500ml acetone and treated 20 with 25001 of a saturated solution of sodium bicarbonate and 17.5( of sodium bicarbonate (MW: 84.01, 208mmol) . The mixture was cooled to 50C and treated drop wise with 26.08g of benzy. chloroformate (MW:170.59, 152mmol) . The reaction was allowed to stirred at room temperature for two hours 25 and monitored by TLC (hexane/ethyl acetate 3:1). The acetone was evaporated, the residue diluted with 5 0ml water, and the solid filtered off. The crystals were washed with 500 1 water and dried. Yield; 48.05g, 95.8%. MS: 352.5 (M+H)*, 50.8, (M-H)-. Method ESI*, ESI~.

17 Step 2: (5R)-3-(4-benzyloxy-3-fluoro-phenyl)-5-hydroxy methyl-oxazolidin-2-one: A stirred solution of 17.5g (4-benzyloxy-3-fluoro-phenyl) 5 carbamic acid benzyl ester (W: 351.38, 50mmol) in 30ml of dry tetrahydrofuran was cooled to -78 0 C with a dry ice/acetone bath. 22.8ml of a 2.3M n-butyl-lithium solution in n-hexane (52.5mmol) was added drop wise and the reaction mixture stirred at - 78 OC for 15 min. 7.92g R(-)-glycidyl 10 butyrate (MW: 144.17, 60mmol) were added and the reaction was allowed to warm up to room temperature. The reaction was monitored by HPLC, quenched with a saturated ammonium chloride solution and diluted with 100ml of ethyl acetate. The organic layer was washed with 200ml water and 200ml 15 brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate evaporated under reduced pressure. The residue was crystallized from 200ml of a 1/1 ethyl acetate/hexane mixture. The solid was collected and recrystallized from 150ml of a 9/1 ethyl acetate/dichloro 20 methane mixture. The colorless crystals were collected and dried. Yield: 10.4-g, 65.5%. MS: 318.1 (M+H)*. Method ESI*. Step 3: (5S)-5-azidomethyl-3- (4-benzyloxy-3-fluoro phenyl)-oxazolidin-2-one: 25 A solution of 10g (5R)-3-(4-benzyloxy-3-fluoro-pheryl)-5 hydroxymethyl-oxazolidin-2-one (MW: 317.32, 31.51mmol) and 4.78g triethylamine (MW: 101.19, 47.26mmol) in 300mln dichloromethane was treated under stirring at 10*C with 4.32g of methane sulfonyl chloride (MW: 114.55, 37.82mmol). 30 The reaction was stirred at room temperature for one hour and monitored by TLC (ethyl acetate: hexane 1:1). The reaction mixture was quenched with 100ml water and the organic layer washed with 100ml brine. The organic layer 18 was dried over magnesium sulfate, filtered and the filtrate evaporated under reduced pressure. The residue was dissolved in 100ml dimethylformamide, 5.12g sodium azide (MW: 65.01, 78.7mmol) and a catalytic amount of tetrabutyl 5 ammonium iodide were added. The suspension was stirred at 90 OC over night. The reaction was monitored by HPL . The dimethylformamide was evaporated under reduced pressure, the residue dissolved in 200ml dichloromethane and the organic layer washed successively with 100ml water and 10 100ml brine. The dichloromethane solution was dried over magnesium sulfate, filtered, and the filtrate evaporated under reduced pressure. The residue was crystallized from 150ml of a 1/1 mixture of ethyl acetate: hexane. The crystals were collected to afford an off white solid. 15 Yield: 10.4-g, 97%. MS: 343.1 (M+H)*-. Method: ESI*. Step 4: U-[(5S)-{3-(3-fluoro-4-hydroxy-phenyl)}-2-oxo oxazolid:,n-5-ylmethyl]-acetamide: A suspension of 10.4g (5S)-5-azidomethyl-3- (4-benzyloxy-3 20 fluorophonyl)oxazolidin-2-one (MW: 342.33, 30.38mmcl) and 1.5g of palladium 10% on activated carbon in 400ml of a 1:1 methanol ethyl acetate mixture was stirred at room temperature under hydrogen for two days. The catal st was filtered off using a glass fibre filter paper and the 25 filtrate evaporated under reduced pressure. The reEidue was dissolved in 100ml of acetic acid, and treated with 3.72g of aceti anhydride (MW: 102.09, 36.45mmol) . The solvent was evap rated under reduced pressure and the residue crystallized from a 1:1 ethyl acetate: hexane mixture to 30 afford an off white solid. Yield: 6.76-g, 83%. MS: 269.4 (M+H)*, 267.3, '(M-H)-. Method ESI, ESI.

19 Step 5: 4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin 3-yl]-2-fluoro-phenoxymethyl}-4-hydroxy-piperidine-1 carboxylic acid benzylester: A suspension of 22.72g 1-oxa-6-aza-spiro[2.5]octane-6 5 carboxylic acid benzyl ester (W09803507) (MW: 247.29, 92mmol), 21.45g N-[(5S)-{3-(3-fluoro-4-hydrcxy-phenyl))-2 oxo-oxazolidin-5-ylmethyl]-acetamide (MW: 268.246, 80mmol) and 16.58g potassium carbonate (MW: 138.20, 120mmol) in 150ml dimethylformamide was stirred at 100 0 C for 7 hours. 10 The reaction was monitored by TLC (dichloromethane / methanol 9:1). The dimethylformamide was evaporated under reduced pressure and the residue was dissolved in 600ml of a 9:1 dichloromethane /methanol mixture. The organic layer was washed with 400ml water and 400ml brine. The organic 15 layer was dried over magnesium sulfate, filtered, and the filtrate diluted with 250ml ethyl acetate. The mixture was concentrated under reduced pressure to a final volume of 400ml. The slurry was stirred at room temperature over night. The crystals were filtered and washed successively 20 with 150ml ethyl acetate and 100ml pentane. Yield: 31.65 g, 76.7%. MS: 516.8 (M+H)+, Method ESI*. Step 6: N- [((5S)-3[3-fluoro-4-(4-hydroxy-piperidin-4-yl methoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}]-acetamide: 25 A suspension of 31g 4-{4-[(5S)-5-(acetylamino-methyl)-2 oxo-oxazolidin-3-yll-2-fluorophenoxymethyl)-4-hydroxy piperidine-l-carboxylic acid benzylester (MW: 515,54 60.13mmol) and 2.5 g of palladium 10% on activated carbon in 310ml methanol and 150ml ethyl acetate was stirred under 30 hydrogen for 4 hrs. The reaction was monitored by TLC (ethyl acetate). The reaction slurry was diluted with 300ml methanol, warmed to 40 0 C, and the catalyst filtered off using a glass fibre filter paper. The filtrate was 20 concentrated to 150ml, diluted with 300ml ethyl acetate and concentrated again to 200ml. 200ml of diethyl ether were added, ard the suspension was cooled to 0*C under stirring. The solic was collected and dried. Yield: 21.6-g, 91.3%. 5 MS: 382.E (M+H)*, Method ESI*. Step7: 7- (4-{1(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin 3-y1]-2- luoro-phenoxymethyl}-4-hydroxy-piperidin-1-yl)-1 cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8] naphthyridine 10 3-carboxylic acid: A suspension of 71mg 7-chloro-l-cyclopropyl-6-fluoro-1,4 dihydro- -oxo-[1,8lnaphthyridine-3-carboxylic acid (MW: 282.66, 0.25mmol ), 95mg N-[{(5S)-3[3-fluoro-4-(4-hydroxy piperidin-4-ylmethoxy)-phenyll-2-oxo-oxazolidin-5 15 ylmethyl ]-acetamide (MW: 381.40, 0.25mmol) 102mg triethyl mine (MW: 101.19, 1.Ommol ) and 81mg trimethy chlorsilan (MW: 108.64, 0.75mmol) in 1ml E-methyl pyrrolidin-2-one was heated at 800C under stirring for 5 hours. The reaction was monitored by TLC (dichloronethane: 20 methanol 9:1). The N-methyl-pyrrolidin-2-one was evaporated, the residue dissolved in 20ml of a 9:1 dichloronethane : methanol mixture, and the solution washed sequentially with 10ml of 0.1 N aqueous hydrochloric acid and 2Qml brine. The organic layer was dried over magnesium 25 sulfate, filtered and the filtrate evaporated. The residue was diss lved in 10ml of a 9:1 dichloromethane: methanol mixture and diluted with 20ml ethyl acetate. The precipitated solid was collected to afford an off white solid. A second crop is obtained by concentration under 30 reduced pressure of the mother liquor. Yield: 100m , 64%. MS: 628.8 (M+H)*, 626.8. (M-H)- Method ESI*, ESI~ 21 Example 2: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-ox oxazolidin-3-yl-2-fluoro-phenoxymethyl}-4-phosphonooxy piperidin-1-yl)-l-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro {1,8]naphthyridine-3-carboxylic acid F 0 0 0 0 NI04 N OH /0 N0 / o F I'-0

N

5 HO OH Step 1: 7-(4-(4-f(5S)-5-(Acetylamino-methyl)-2-oxo oxazolidin-3-yl]-2-fluoro-phenoxymethyl)-4-(bis-benzyloxy phosphoryloxy)-piperidin-1-yl]-1-cyclopropyl-6-fluoro-4 10 oxo-1,4-dihydro-[1,8]naphthyridine -3-carboxylic acid: A suspension of 125mg 7-(4-{{(5S)-5-(acetylamino-methyl)-2 oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl)-4-hydroxy piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro [1,8]naphthyridine-3-carboxylic acid (MW: 627.60, 0.2mmol) 15 and 42mg tetrazole (MW:70.05, 0.Gmmol) in Iml dichloromethane was treated with 138mg of dibenzyl N,N dilsopropylphosphoramidite (MW: 345.42, 0.4mmol). The original suspension slowly cleared. The solution was stirred at room temperature for two hours and monitored by 20 TLC. (dichloromethane/methanol 9:1). The reaction mixture was cooled to 0*C and treated with a 0.6ml of a 0.5M m chloroperbenzoic acid solution in dichloromethane. The mixture was stirred for two hours at room temperature and diluted with 20ml dichloromethane. The organic layer was 25 washed successively with 20ml of a saturated aqueous sodium bicarbonate solution and 20ml of brine and dried over magnesium sulfate. The slurry was filtered and the filtrate evaporated under reduced pressure. The residue was purified by chromatography over silica using a 9/1 dichloro- 22 methane/methanol mixture as eluent to afford an off white solid. Yield: 158mg, 89%.MS: 889.3 (M+H) 4 , 887.0 (M-H)~ Method E;I, ESI~. 5 Step 2: "-(4-{4-[(5S)-(5-Acetylamino-methyl)-2-oxo oxazolid:.n-3-yl]-2-fluoro-phenoxymethyl1-4-phosphonoxy piperidin-1-yl)-l-cyclopropyl-6-fluoro-4-oxo-1,4-di ydro [1,8)naphthyridine -3-carboxylic acid: A suspension of 158mg 7-{4-{4-[(5S)-5-(Acetylamino- ethyl) 10 2-oxo-oxazolidin-3-yll-2-fluoro-phenoxymethyl}-4-(bis benzyloxr-phosphoryloxy) -piperidin-1-yl] -1-cycloprcpyl-6 fluoro-4 -oxo-1,4-dihydro-11,8] naphthyridine -3-carboxylic acid (MW: 887,84, 0.177mmol) and 20mg of palladium hydroxide 20% on activated carbon in 20ml of a 6/3/1 15 dichloronethane/methanol/ water mixture was stirred at room temperature under hydrogen for three hours. The catalyst was filtered off using a glass fibre filter paper. The solvents were evaporated under reduced pressure anc the residue dissolved in 10ml methanol. The solution was 20 diluted with 20ml water while a white solid precipitated. The solid was collected and dried. Yield: 85mg, 68%. MS: 709.0 (M+H)*, 706.5 (M-H)~ Method ESI*, ESI~. Example 3: 7-[4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo 25 oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-(2,6-dinmino hexanoyloxy)-piperidin-1-yl-1-cyclopropyl-6-fluoro-4-oxo 1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid 23

NH

2

H

2 N 0 N 0O H F 0 OH Step 1: 4-{4- [(58) - (5-Acetylamino-methyl) -2-oxo-oxazolidin 3-ylJ-2-fluoro-phenoxymethyl}-4-hydroxy-piperidine-l 5 carboxylic acid tert-butyl ester: In analogy of example I step 5 by reacting 3.83g 1-oxa-6 aza-spiro[2.5loctane-6-carboxylic acid tert-butyl ester (WO0204462) (MW: 213.28 18mmol), 4.02g N-[(5S)-(3-(3 fluoro-4-hydroxy-phenyl)}-2-oxo-oxazolidin-5-ylmethyl] 10 acetamide (MW: 268.246, 15mmol) and 3.lg potassium carbonate (MW: 138.20, 22.5mmol) in 30ml dimethylformamide. Yield: 4.89-g, 67%. MS: 482.6 (M+H)+, Method ESI+. Step 2: 4-(4- [(58) -5- (Acetylamino-methyl) -2-oxo-oxazolidin 15 3-yl] -2-fluoro-phenoxymethyl}-4- (2,6-bis benzyloxycarbonylamino-hexanoyloxy) -piperidine-1-carboxylic acid tert-butyl ester: A suspension of 96mg of 4-{4- 15- (58)- (acetylamino-methyl) 2-oxo-oxazolidin-3-yl -2-f luoro-phenoxymethyl}-4-hydroxy 20 piperidine-l-carboxylic acid tert-butyl ester (MW: 481.52, 0.2mmol), 195mg of Z-Lys (Z)-OH (MW: 414.46, 0.4mmol) and 49mg of 4-dimethylaminopyridine (MW: 122.17, 0.4mmol) in 2ml dichloromethane was treated under stirring at room temperature with 115mg N- (3-dimethylaminopropyl) -N'-ethyl 25 carbodiimid hydrochloride (MW: 191.70, 0.6mmol). The reaction mixture was stirred over night. The mixture was 24 diluted with 20ml ethyl acetate and the organic layer washed s ccessively with 10ml 1 N aqueous hydrochloric acid, 20r1 water and 20ml brine. The organic layer was dried over magnesium sulfate, filtered and the filt ate 5 evaporatEd to dryness. The residue was purified by chromatography on silica, using a 9/1 dichloromethaie/ methanol mixture as eluent to leave a colorless sticky oil. Yield: 1 0mg, 88%. MS: 878.8 (M+H)*, Method ESI*. 10 Step 3: 2,6-Bis-benzyloxycarbonylamino-hexanoic acid 4-{4 (5S) -5- acetylamino-methyl) -2-oxo-oxazolidin-3-yl] -2 fluoro-phenoxymethyl)-piperidin- 4 -yl ester hydrochloride: 200mg of 4-{4-[5-(5S)-(acetylamino-methyl)-2-oxo oxazolid:.n-3-yl]-2-fluoro-phenoxymethyl-4- (2,6-bis 15 benzylox carbonylamino-hexanoyloxy) -piperidine-l-carboxylic acid tert-butyl ester (MW: 977.97, 0.22mmol) were dissolved in 4ml of a 1.25M dry hydrochloric acid in methanol. The reaction was stirred at 400C for two hours, and the solvent removed by distillation under reduced pressure to leave a 20 off white solid. Yield: 178mg, quantitative. MS: 758.8 (M+H)+, Method ESI*. Step 4: 7-[4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo oxazolid'n-3-yl)-2-fluoro-phenoxymethyl)-4-(2,6-bi 25 benzyloxFcarbonylamino-hexanyloxy) -piperidin-1-yl] -1 cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine 3-carbox lic acid: In analogy to example 1 step 7, with 62mg 7-chloro--1 cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- [1,8)naphthyridine 30 3-carboxylic acid (MW:282.66, 0.25mmol), 178mg 2,6.-bis benzylox ycarbonylamino-hexanoic acid 4- (4- 15- (5S) - acetyl amino-methyl) -2-oxo-oxazolidin-3-yl] -2-fluoro-phenoxy methyl}- iperidin-4-yl ester hydrochloride (MW: 814.31, 25 0.22mmol), 90mg triethylamine (MW: 101.19, 0.88mmol ) and 48mg trimethylchlorsilan (MW: 108.64, 0.44mmol) in iml N methyl-pyrrolidin-2-one. Yield: 94mg, 42%. MS: 1025.3 (M+H)*, Method ESI*. 5 Step 5: 7-[4-{4-{(5S)-5-(Acetylamino-methyl)-2-oxo oxazolidin-3-yl]-2-fluoro-phenoxymethyl)-4-(2,6-diamino hexanoyloxy)-piperidin-1-yll-l-cyclopropyl-6-fluoro-4-oxo 1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid: 10 A suspension of 94mg 7-[4-(4-[(SS)--(acetylamino-methyl) 2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl)-4- (2,6-bis benzyloxycarbonylamino-hexanoyloxy)-piperidin-1-yll-1 cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,Blnaphthyridine 3-carboxylic acid (MW; 1024.05, 0.091mmol) and 20mg of 15 palladium hydroxide 20% on activated carbon in 20ml of a 6/3/1 dichloromethane/methanol/water mixture was stirred at room temperature under hydrogen for four hours. The catalyst was filtered off using a glass fibre filter paper. The solvents were evaporated under reduced pressure and the 20 residue dissolved in 10ml methanol. The solution was diluted with 20ml water while a white solid precipitated. The solid was collected and dried. Yield: 29mg, 43%. MS: 757.0 (M+H)*, 755.2 Method ESI*, ESI. 25 Example 4: Succinic acid mono-[4-(4-[(5S)-5-(acetylamino methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl} -1 (6-carboxy-8-cyclopropyl-3-fluoro-5-oxo-5,8-dihydro [1,8]naphthyridin-2-yl)-piperidin-4-yl) ester 26 OH o 0 F 0 N '1 0 N H F N N0 0 OH Step 1: succinic acid 4-{4-(5S)-5-(acetylamino-metyl)-2 oxo-oxazolidin-3-yll-2-fluoro-phenoxymethyl)-1-tert-butoxy 5 carbonyl--piperidin-4-yl ester benzyl ester: In analogy of example 3 step 2 with 825mg 4-{4-[(SS)-5 (acetylaino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluor phenoxymEthyl}-4-hydroxy-piperidine-l-carboxylic acid tert butyl ester (MW: 481.52, 1.71mmol), 1.07g of succinic acid 10 monobenzyl ester (MW: 208.21, 5.14mmol) and 0.63g of 4 dimethylaminopyridine (MW: 122.17, 5.1mmol) in 1Ml dichloromethane was treated under stirring at room temperature with 1.3g N-(3-dimethylaminopropyl)-N'-ethyl carbodii-nid HCI (MW: 191.70, 6.8mmol). Yield; 820mc, 70%. 15 MS: 673.3 (M+H)*, Method ESI*. Step 2: guccinic acid 4-{4-[(5S)-5-(acetylamino-methyl)-2 oxo-oxazolidin-3-yll-2-fluoro-phenoxymethyl}-piperjdin-4-yl ester beazyl eater: 20 820mg of succinic acid 4-(4-[(5S)-5-(acetylamino-m thyl)-2 oxo-oxazolidin-3-yll-2-fluoro-phenoxymethyl}-1-tert,-butoxy carbonyl-piperidin-4-yl ester benzyl ester (MW: 67:.72, 1.23mmol) were dissolved in 4ml of trifluoro acetic acid. The reaction mixture was stirred at room temperature for 25 one hou . The solvent was evaporated, the residue dissolved in 30ml of a 9/1 dichloromethane/methanol mixture and the 27 organic layer washed successively with 30ml of a saturated aqueous sodium bicarbonate solution and 30ml of brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate evaporated under reduced pressure. The 5 residue was purified by chromatography over silica, using a 95/5 dichloromethane/ methanol mixture with 2% triethylamine as eluent. Yield: 420mg, 60%. MS: 572.7 (M+H)+, Method ES1 4 . 10 Step 3: Succinic acid 4-{4-[(5S)-5-(acetylamino-methyl)-2 oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-1-(6-carboxy 8-cyclopropyl-3-fluoro-5-oxo-5,8-dihydro-{1,8]naphthyridin 2-yl)-piperidin-4-yl ester benzyl ester: In analogy to example 1 step 7, with 113mg 7-chloro-1 15 cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-[1,8]naphthyridine 3-carboxylic acid (MW:282,66, 0.4mmol ), 230mg succinic acid 4-{4-[(SS)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3 yl]-2-fluoro-phenoxymethyl}-piperidin-4-yl ester benzyl ester (MW: 571.60, 0.4mmol), 161mg triethylamine (MW: 20 101.19, 1.6mmol ) and 87mg trimethylchlorsilan (MW: 108.64, 0.8mmol) in 2ml N-methyl-pyrrolidin-2-one. Yield: 25mg, 7.6%. MS: 819 (M+H)*, 817.8, Method ESI*, ESI. Step 4: Succinic acid mono-[4-(4-[(5S)-5-(acetylamino 25 methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-1 (6-carboxy-8-cyclopropyl-3-fluoro-5-oxo-5,8-dihydro [1,8]naphthyridin-2-yl)-piperidin-4-yl] ester: In analogy to example 3 step 5 with 22mg succinic acid 4 {4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2 30 fluoro-phenoxymethyl)-1-(-carboxy-8-cyclopropyl-3-fluoro 5-oxo-5,8-dihydro-{1,8]naphthyridin-2-yl)-piperidin-4-yl ester benzyl ester (MW: 817.80, 0.026mmol) and 2mg of palladium hydroxide 20% on activated carbon in 20ml of a 28 1/1 tetra ydrofuran/ methanol mixture. Yield: 16mg, 81%. MS: 729 (4+H)*, 727 (M+H)~, Method ESI*, ESI~. Example 5: 7-(4-(4-[(S)-5-(Acetylamino-methyl) -2 -oo 5 oxazolidin-3-yl] -2-fluoro-phenoxymethyl}-4-hydroxy piperidir-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro quinoline -3-carboxylic acid o N F tFjH NH HO N O4 0 1 10 A solution of GOg N- [{ (5S) -3 [3-fluoro-4- (4-hydroxy piperidiu-4-ylmethoxy) -phenyl] -2-oxo-oxazolidin-5 ylmethyl ]-acetamide. (CiaI 24 FN30s, MW: 381.40 0.157 mole) and 26.87ml of ethyl diisopropylamine (MW: 129.25, 0.157 mole) in 300ml N-methyl-pyrrolidin-2-one was treated with 15 67.81g ( 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydrc -4-oxo 3-quinolinecarboxylic acid-boron diacetate complex (MW:410.57, 0.165 mole) and the mixture was stirred at 80oC for 5 hours. The N-methyl-pyrrolidin-2-one was evaporated under reduced pressure and residue was dissolved in 300ml 20 of methanol. Anhydrous hydrogen chloride was bubbled through the solution at 10 OC for 30 minutes. The solution was stirred at room temperature while a yellow solid precipitated. The conversion of the boron complex to the free acid was monitored by HPLC. The mixture was diluted 25 with 30Cml ethyl acetate. The solid was filtered and washed with 10(ml of 8/2 ethyl acetate/methanol and 100ml of ethyl acetate. The yellow solid was dried to leave 86.4 g of a yellow colid. The solid was dissolved in 200ml dimethy sulfoxyde at 40 OC, and the yellow solution was 29 added under stirring to 1000ml water. The yellow solid was collected, washed with water and dried. Yield: 73g, 74.5%. MS: 627.8 (M+H) 4 , 625.8 (M+H)-, Method ESI*, ESI. 5 Example 6: 7-[4-(4-[(5S)-5-(Acetylamino-methyl)-2-oxo oxazolidin-3-yl] -2-fluoro-phenoxymethyl}-4- (bis-benzyloxy phosphoryloxy) -piperidin-1-yll -l-cyclopropyl-6-fluoro-4 oxo-1, 4-dihydro-quinoline-3-carboxylic acid 0 F 0 N ONO0 N OH NH O4 00 10 A suspension of 35g 7- (4-(4- [(5S) -5- (acetylamino-methyl)-2 oxo-oxazolidin-3-y1 -2-fluoro-phenoxymethyl}-4-hydroxy piperidin-1-yl) -1-cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro guinoline-3-carboxylic acid (MW: 626.61, 55.85mmol) and 15 6,45g tetrazole (MW: 70.05, 92.15mmol) in 700ml dichloromethane was treated at room temperature under stirring with a solution of 31.8g dibenzyldiisopropylphosphoramidit (MW: 345.42, 92.15mmol) in 20ml dichloromethane, The reaction was monitored by TLC 20 (dichloromethane/methanol 9:1). The reaction was stirred for one hour and the mixture was washed at DOc with 200ml IN aqueous hydrochloric acid and 100ml of a saturated sodium bicarbonate solution. The water layer were backwashed with 200ml dichloromethane. The combined organic 25 layer were concentrated to 500ml and treated at roomtemperature with 13,2ml of a 70 % ter-butyl hydroperoxid solution in water (MW:90.12, 95mmol). The 30 reaction was stirred for 30 min, diluted with 500ml dichloromethane and the organic layer washed with 2COmi 1N aqueous hydrochloric acid and with 300ml brine. The organic layer was dried over magnesium sulfate, filtered anc the 5 filtrate evaporated under reduced pressure. The residue was dissolved in 400ml dichloromethane and diluted with 400ml N-hexane. The mixture was concentrated (300-mbar, 4 0 1C bath temperature) to a volume of 400ml. The sticky oil was decanted and dissolved in 400m of refluxing methanol. The 10 solution was concentrated to 300ml under reduced pressure and stirred over night at RT. The slurry was cooled to OC and the solid collected. Yield: 27.60g, 55.6%. MS: 888.3 (M+H)*, 835.8 (M+H), Method ESI*, ESI~. 15 Example 7-(4-(4-[(5S)-5-(Acetylamino-methyl)-2-o:co oxazolidin-3-yll-2-fluoro-phenoxymethyl}-4-phosphonooxy piperidiT-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-di ydro quinolinE-3-carboxylic acid F 0 N O N OH N-/ F _ H ,,P =0 HO \ OH 20 27g 7-{4.(4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin 3-yll-2- luoro-phenoxymethyl}-4-(bis-benzyloxy phospho rloxy)-piperidin-1-yl]-l-cyclopropyl-6-fluoro-4 oxo-1,4-dihydro-quinoline-3-carboxylic acid (MW: 886.85, 25 30.44mmo.) were suspended in 600ml acetonitrile and treated with 53m of a 33% solution of anhydrous hydrobromic acid in aceti, acid. The yellow suspension was diluted with 150ml of acetic acid and was heated to 450C. The reaction was moni ored by HPLC/MS and was complete after 3 hours.

31 The sticky suspension was added to 1.5 L of water under stirring. The off white crystals were collected, washed with 300ml water, 150ml ethanol and 150ml ether. The solid was suspended in 1.3L water and treated with 35ml (35mmol) 5 of a 1M aqueous sodium hydroxide solution. The solid dissolved, and the brown-yellow solution was treated with 15 g of activated charcoal and filtered. The filtrate was extracted with 3 portions of 200ml of a 95/5 dichloromethane/ methanol mixture. The water layer was 10 treated with 40ml of 1 M HC1 solution and the product crystallized by stirring. The solid was collected and dried. Yield: 17.3-9, 80.4 %. MS: 609.7 (M+H)*, 607.8 (M+H) , Method ESI+, ESI~. 15 Example 8: 7-(4-(4-{(SS)-5-(Acetylamino-methyl)-2-oxo oxazolidin-3-yl] -2-f luoro-phenoxymethyl} -4-hydroxy piperidin-1-yl) -l-cyclopropyl-6-fluoro-8 -methoxy-4-oxo-1, 4 dihydro-quinoline-3-carboxylic acid 0 F NH F HO O N O N 0 -o N OH 0 20 In analogy to example 5 with 114mg N- [{ (5S) -3 [3-fluoro-4 (4-hydroxy-piperidin-4-ylmethoxy)-phenyll-2-oxo-oxazolidin 5-ylmethyl}]-acetamide. (MW: 381.40 0.3mmol), 127mg of 1 cyclopropyl-6, 7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3 25 quinolinecarboxylic acid diacetylborate (Sakurai, Nobuhiro; Sano, Mitsuharu; Hirayama, Fumihiro; Kuroda, Tsuyoshi; Uemori, Satoru; Bioorg.Med.Chem.Lett.; 8; 16; 1998; 2185 2190) (MW: 423.137, 0.3mmol) and 38mg of ethyl 32 diisopropylamine (MW: 129.25, 0.3mmol) in 1ml N-methyl pyrrolid:.n-2-one. Yield: 137mg, 69.5 %. MS: 658.2 (3M+H)*, 655.8 (M--H), Method ESI*, ESI~. 5 Example 9: 7 -(4-(4-1(5S)-5-(Acetylamino-methyl)-2-o o oxazolid n-3-yl] -2-fluoro-phenoxymethyl}-4-hydroxy piperidin-1-yl) -1-cyclopropyl-8-methoxy- 4 -oxo-1, 4-dihydro quinolin -3-carboxylic acid 100 NHF HO N *\ /AI;0 -o N O 10 In analogy to example 5 with 114mg N-[{(5S)-3[3-fll oro-4 (4-hydroxy-piperidin-4-ylmethoxy) -phenyll -2-oxo-oxe zolidin 5-yl-methyl}]-acetamide. (MW: 381.40 0.3mmol), 121mg of 1 cycloprc pyl-8-methoxy-4-oxo-1, 4-dihydroquinoline-3 15 carboxylatoboron diacetate (WO03032962) (MW: 405.1E, 0.3mmol) and 77mg of ethyl diisopropylamine (MW: 1:9.25, 0.6mmol) in 2ml N-methyl-pyrrolidin-2-one. Yield; 17mg, 61.2 %. MS: 639.8 (M+H)*, 637.5 (M+H)~, Method ESI* ESI~. 20 Example 10: 9 -(4-{4-[(SS)-5-(Acetylamino-methyl)-2 oxo oxazoli in-3-yl] -2-fluoro-phenoxymethyl)-4-hydroxy piperidin-1-yl)-8-fluoro-3-methyl-6-Oxo-2,3-dihydro-6H-1 oxa-3a- za-phenalene-5-carboxylic acid 0 A F A NH F HO - 0 N \ N O 0 0 N O 0 33 A solution of 140mg of 9-10-difluoro-2,3-dihydro-3-methyl 7-oxo-7H-pyrido[1,2,3-del-1,4-benzoxazine-6-carboxilic acid (MW; 281.22, 0.5mmol), 191mg of N-[{(5S)-313-fluoro-4-(4 5 hydroxy-piperidin-4-ylmethoxy) -phenyl] -2-oxo-oxazolidin-5 yl-methyl}]-acetamide (MW: 381.40, 0.5mmol), and 129mg of ethyl diisopropylamine (MW: 129.25, 1mmol) was stirred at 80 0 C in Iml of N-methyl-pyrrolidin-2-one for 24 hours. The solvent was evaporated under reduced pressure. The residue 10 was dissolved in methanol and treated with 10ml of a 1.2 M anhydrous hydrogen chloride solution in methanol. The methanol was evaporated and the residue digested in ethyl acetate. The solid was collected and crystallized twice from a dichloromethane/ethanol mixture. Yield: 88mg, 27 %. 15 MS: 643.7 (M+H)*, 641.5 (M+H)~, Method ESI*, ESI~. Example 11: 7-(3-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo oxazolidin-3-yll -2-fluoro-phenoxymethyl}-3-hydroxy pyrrolidin-1-yl) -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro 20 [1,83naphthyridine-3-carboxylic acid 0 HO F ON -Q N N N , H N O T F 4 Step 1: 1-Oxa-5-aza-spirol2.4]heptane-5-carboxylic acid benzyl ester: 25 A solution 3-methylen-pyrrolidine-l-carboxylic acid benzyl ester (WO9624593) in 5ml of dichloromethane was treated with 2.16g sodium bicarbonate (MW: 84.01 26.28mmol) and 2.47g of 80% m-chlor-perbenzoic acid (MW: 172.57, 11.48mmol) .The reaction mixture was stirred at room temperature for three 34 hours. The reaction mixture was diluted with 20ml ol a saturated aqueous sodium sulfite solution and 45ml cf dichloronethane. The organic layer was successively washed with 30ml of an aqueous saturated sodium bicarbonate 5 solution and brine. The organic layer was dried ove: magnesiu. sulfate. The residue was purified by chromatography on silica (1/1 ethyl acetate/n-hexane) to afford a off white solid. Yield: 440mg, 57 %, MS: 234.1(M+I)*, Method ESI+. 10 Step 2: -'{4-((5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin 3-yll -2- luoro-phenoxymethyl)-3-hydroxy-pyrrolidine-1 carboxyl:c acid benzyl ester: A solution of 420mg of N-[(SS)-{3-(3-fluorO-4-hydroxy 15 phenyl) }2-oxo-oxazolidin-5-ylmethyll-acetamide (KW: 268.246, 1.56mmol) in 2ml dimethylformamide was treated with 83mg sodium hydride. The suspension was stirred for one hour at room temperature, A solution of 440mg 2-oxa-5 aza-spir>[2.4]heptane-5-carboxylic acid benzyl ester (MW: 20 233.26, .88mmol) in 1ml DMF was added and the mixture was stirred at 700C for three hours. The dimethylformamide was evaporat d under reduced pressure and the residue was purified by chromatography over silica (95/5 dichloronethane/methanol mixture with 1% ammonia) to afford 25 an off white powder. Yield: 630mg, 80 %. MS: 502.5 (M+H)*, Method ESI*. Step 3: N-((5S)-3-{3-Fluoro-4-(3-hydroxy-pyrrolidin-3-yl methoxy)-phenyll-2-oxo-oxazolidin-5-ylmethyl}-acetamide: 30 A suspension of 660mg 3-{4-[(5S)-5-(acetylamino-me hyl)-2 oxo-oxa olidin-3-yll-2-fluoro-phenoxymethyl)-3-hydroxy pyrrolicine-1-carboxylic acid benzyl ester (MW: 501.51, 1.31mmo]) and 20mg palladium 10% on activated carb n in 35 20ml of a 1/1 ethyl acetate / methanol mixture was stirred for twelve hours under hydrogen. The catalyst was filtered on a glass fiber filter paper and the filtrate evaporated under reduced pressure to afford a colorless oil. Yield: 5 400mg, 83.2 %. MS: 368.4 (M+H)*, Method ESI+. Step 4. 7-(3-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo oxazolidin-3-yl] -2-f luoro-phenoxymethyl} -3-hydroxy pyrrolidin-1-yl) -l-cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro 10 [1, 8]naphthyridine-3-carboxylic acid: In analogy to example 1, step 7 with 39mg 7-chloro-1-cyclo propyl-E-fluoro-1, 4-dihydro-4-oxo-[1,8]naphthyridine-3 carboxylic acid (MW: 282.66, 0.24mmol ), 99mg N-{(5S)-3-[3 fluoro-4- (3-hydroxy-pyrrolidin-3-ylmethoxy) -phenyl] -2-oxo 15 oxazolidin-5-ylmethyl)-acetamide. (MW: 367.38, 0.24mmol) 101mg triethylamine (MW: 101.19, 1.Ommol) and 80mg trimethylchlorsilan (MW: 108.64, 0.75mmol) in 2ml N-methyl pyrrolidin-2-one. Yield: 70mg, 46 %. -MS: 614.7(M+H)*, 612.7 (M+H)~, Method ESI+, ESI. 20 Example 12: 7-(3-(4-[(SS)-5-(Acetylamino-methyl)-2-oxo oxazolidin-3 -yll -2 -fluoro-phenoxymethyl ) -3 -hydroxy pyrrolidin-1-yl) -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro quinoline-3-carboxylic acid 0 F 0 AN O 1- N / 0 H HO 0 F N 0

.

/OH 25 In analogy to example 5 with 106mg N-((SS)-3-[3-fluoro-4 (3-hydroxypyrrolidin-3-ylmethoxy) -phenyl] -2-oxo-oxazolidin 5-ylmethyl}-acetamide. (MW: 367.38, 0.29mmol) 119mg (7- 36 chloro-1- :yclopropyl-6-fluoro-1,4-dihydro-4-oxo- 3 quinoline arboxylic acid-boron diacetate complex (MW:410.57, 0.29mmol) and 75mg of ethyl diisopropylamine (MW: 129.25, 0.58mmol) in 2ml N-methyl-pyrrolidin-2-one. 5 Yield: 19ng, 11 %.MS: 613.5 (M+H) t , 611.5 (M+H)", Method ESI*, ESI'. Example 13: 7-(3-(4-[(55)-5-(Acetylamino-methyl)-2 -xo oxazolidin-3-yl] -2-fluoro-phenoxymethyl}-3-hydroxy 10 pyrrolidia-1-yl) -i-cyclopropyl-6-fluoro-8-methoxy- 4 -oxo 1, 4-dihy ro-quinoline-3-carboxylic acid 0 OAN CO N F 0 F~ /0 NH -o N OH In analogy to example 5 with 143mg N-{(5S) -3-[3-flU ro-4 15 (3-hydro -pyrrolidin-3-ylmethoxy) -phenyl) -2-oxo oxazolid:.n-5-ylmethyl}-acetamide (MW: 367.38, 0.39mol), 165mg of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy 4-oxo-3-quinolinecarboxylic acid diacetylborate (MW: 423.137, 0.39mmol) and 100mg of ethyl diisopropylamine (MW: 20 129.25, 0.78mmol) in 2ml N-methyl-pyrrolidin-2-one. Yield: 143mg, 5 %. MS: 643.7 (M+H)+, 641.7 (M+H)-, Method ESI, ESI". Example L4: 7-(3-(4-[(SS)-5-(Acetylamino-methyl)-2-oxo 25 oxazolid n-3-yl]-2-fluoro-phenoxymethyl)-3-hydroxy pyrrolidin-1-yl) -1-cyclopropyl-8-methoxy-4-oxo-1, 4 -dihydro quinoline-3-carboxylic acid 37 0 -- - O N H -0 N O 0 In analogy to example 5 with 48mg N-{(SS)-3-[3-fluoro-4-(3 hydroxy-pyrrolidin-3-ylmethoxy) -phenyl] -2-oxo-oxazolidin-5 5 ylmethyl}-acetamide (MW: 367.38, 0.13mmol), 53mg of 1 cyclopropyl-8-methoxy-4-oxo-1, 4-dihydroquinoline-3 carboxylatoboron diacetate (MW: 405.15, 0.13mmol) and 33mg of ethyl diisopropylamine (MW: 129.25, 0.26mmol) in Iml N methyl-pyrrolidin-2-one. Yield: 41mg, 50 %. MS: 625.8 10 (M+H)*, 623.8 (M+H)", Method ESI*, ESI. Example 15: 9-(3-(4-{(5S)-5-(Acetylamino-methyl)-2-oxo oxazolidin-3-yl] -2-f luoro-phenoxymethyl)-3-hydroxy pyrrolidin-1-yl)-8-fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1 15 oxa-3a-aza-phenalene-5-carboxylic acid 0 K O N 0 NH O 0 In analogy to example 10 with 110mg of 9-10-difluoro-2,3 dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de) -1, 4-benzoxazine 20 6-carboxilic acid (MW: 281.22, 0.39mmol), 143mg of N-{(5) 3- [3-f luoro-4- (3-hydroxy-pyrrolidin-3-ylmethoxy) -phenyl] -2 oxo-oxazolidin-5-ylmethyl}-acetamide. (MW: 367.38, 0.39mmol), and 100mg of ethyl diisopropylamine (MW: 129.25, 38 0,78mmol) in 2ml of N-methyl-pyrrolidin-2-one. Yield: 103mg, 42 %.MS: 629.8 (M+H)*, Method ESI 4 . Example 16 : 7-(4-4-{(5S)-5-(Acetylamino-methyl)-2 - 0 5 oxazolidin-3-yl] -2-fluoro-phenoxymethyl) -4-hydroxy- zepan 1-yl) -- cyclopropyl-6 -4-oxo-1,4-dihydro-quinline-3 carboxylic acid 0 N F N OO NH F\ N O 0 10 Step 1: 4 -Methylene-azepane-l-carboxylic acid tert-butyl ester: A solution of ig methyltriphenylphosphoniumbromide (MW: 357.22, 2.79mmol) in 20ml of tetrahydrofuran was treated at -780C wit h 1.22ml of a 2.3 M n-butyl lithium soluti n in N 15 hexane (2.8mmol). The reaction mixture was stirred at -780C for ten minutes, then at OC for one hour. The yellow suspension was cooled to -78 0 C and treated with a solution of 595mg 4-oxo-azepane-1-carboxylic acid tert-butyl ester (WO 2000 44376) (MW: 213.279, 2.78mmol) in 10ml 20 tetrahydcofuran. The reaction mixture was stirred at room temperat are for one and half hour. The reaction mixture was quenched with 30ml of a saturated aqueous solution of ammonium chloride, diluted with 30ml of ethyl acetzte. The organic layer was successively washed with 30ml wat er and 25 30ml brine, dried over magnesium sulfate and filtered. The filtrate was evaporated under reduced pressure and the residue purified by chromatography over silica. (cyclohexane:ethyl acetate 1:1). Yield: 487mg, 83% NMR (CDCl 3 ): 1.35 ppm (s, 9 H, tert-but.); 1.6 ppm (m, 2H, -CH 2

-

39 ), 2.14 ppm (m, 2H), 2.33 ppm (M, 2H); 3.29 ppm (m, 4H, N

CH

2 ); 4.67 ppm (m, 2H, vinyl-CH 2 ). Step 2: l-Oxa-6-aza-spiro[2.6]nonane-6-carboxylic acid 5 tert-butyl ester: In analogy to example 11 step 1 with 4-methylene-azepanle-1 carboxylic acid tert-butyl ester (MW:211.307, 1.73mmol), 1.16g sodium bicarbonate (MW: 84.01 13.8mmol) and 1.36g of 80% m-chloroperbenzoic acid (MW172.57, 6.05mmol) in 5ml of 10 dichloromethane. Yield: 250mg, 63 %. MS: 228.8 (M+H)*, 127.8

(M-(CH

3

)

3 COCO) method ESI+. Step 3: 4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin 3-ylJ-2-fluoro-phenoxymethyl)-4-hydroxy-azepane-l 15 carboxylic acid tert-butyl ester: In analogy to example 1 step 5 with 247mg of 1-oxa-6-aza spiro[2.6]nonane-6-carboxylic acid tert-butyl ester. (M W: 227.31 1.08mmol), 296mg N-[(5S)-(3-(3-fluoro-4-hydroxy phenyl))-2-oxo-oxazolidin-5-ylmethyl]-acetamide (MW: 20 268.246, 80mmol) and 228mg potassium carbonate (MW: 138.20, 1.65mmol) in 150ml dimethylformamide. Yield: 334mg, 62 %. MS: 496.8 (M+H)V, 440.8 (M-C(CH 3

)

3 +H)+, Method ESI+. Step 4: N-{(5S)-3-[3-Fluoro-4-(4-hydroxy-azepan-4 25 ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl)-acetamide: A solution of 334mg 4-{4-[(SS)-5-(acetylamino-methyl)-2 oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl)-4-hydroxy azepane-1-carboxylic acid tert-butyl ester (MW:495.55, 0.674mmol) in 3ml of a 1.25 M anhydrous hydrogen chloride 30 solution in methanol was stired at 350C for four hours. The solvent was evaporated under reduced pressure. The residue was dissolved in 4ml water and the water layer neutralized to pH 7 with a saturated sodium bicarbonate solution. The 40 water was evaporated and the residue dissolved in 30ml of a 9/1 dichloromethane/methanol mixture. The unsoluble salt were filt ered and the filtrate evaporated to dryness to afford of f white solid. Yield 266mg, quant. MS: 395,8 5 (M+H)*, 440.6 (M+HCOO), Method ESI*, ESI~. Step 5: - (4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo oxazolid n-3-yl] -2-fluoro-phenoxymethyl) -4-hydroxy- zepan 1-yl) -1- cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinline-3 10 carboxylic acid: In analogy to example 5 with 150mg N-((SS)-3-[3-flU-ro-4 (4-hydro y-azepan-4-ylmethoxy) -phenyll -2-oxo-oxazol idin-5 ylmethyl -acetamide (MW: 395.43) and 98mg of ethyl diisopropylamine (MW: 129.25, 0.758mmol), 163mg (7- hloro 15 1-cyclop opyl-6-fluoro-1,4-dihydro-4-oxo-3 quinolinecarboxylic acid-boron diacetate complex (MW:410.17, 0.397mmol) in 2ml N-methyl-pyrrolidin--2-one. Yield: 70mg, 28.8 %, MS: 641.7 (M+H)*, method ESI*. 20 Example :7: 7-(4-{4-[(5S)-5-(Acetylamino-methyl)-2-oxo oxazolid tn-3-yl] -2-fluoro-phenoxymethyl} -4-hydroxy-azepan 1-yl) -1- yclopropyl-6-fluoro-4-oxo-1,4-dihydro [1,8]nap thyridine-3-carboxylic acid 0 F NO N N 0 F 25 In analogy to example step7 with 98mg 7-chloro-1 cyclopro yl-6-fluoro-1,4-dihydro-4-oxo- [1, 8]naphthyridine 3-carbox lic acid (MW: 282.66, 0.348mmol ), 138mg N-{(5S) 3- (3-flu ro-4- (4-hydroxy-azepan-4-ylmethoxy) -pheny ] -2-oxo- 41 oxazolidin-5-ylmethyl}-acetamide (MW: 395.43, 0.348mmol), 140mg triethylamine (MW: 101.19, 1.39mmol) and 113mg trimethylchlorsilan (MW: 108.64, 1.04mmol) in 1ml N-methyl pyrrolidin-2-one. Yield: 150mg, 77 %. MS: 642.7 (M+H)*, 5 640.7 (M+H)-, Method ESI*, ESI~. Example 18: sodium salt of 7-(4-(4-[(5S)-5-(Acetylamino methyl) -2-oxo-oxazolidin-3-yl] -2-fluoro-phenoxymethyl}-4 phosphonooxy-piperidin-1-yl) -1-cyclopropyl-6-fluoro-4-oxo 10 1,4-dihydro-quinoline-3-carboxylic acid 183 g of the compound of example 7 were dissolved in 400 mL dry DMS at room temperature. Then the solution was treated with 60 g Fullers earth and filtered off. The remaining 15 solid was washed with 50 mL dry DMSO. The combined filtrates were mixed with another 50 mL of dry DMSO and 2000 mL of dry acetone under nitrogen. To this solution a solution of 47.1 g sodium-2-ethylhexanoate (97% in ethyl acetate, i.e. 250 mL) was added drop wise at room 20 temperature. The resulting suspension was then stirred for 1 h, followed by the addition of 2750 mL ethyl acetate at room temperature. The resulting suspension was stirred for another hour and the resulting crystals were collected by filtration, washing the solid with ethyl acetate (10 x 500 25 ml) to remove the DMSO and then dried in vacuo. If thsre is still amounts of DMSO and/or ethyl acetate remaining, then the solid was slurred with acetone / water (99:1) for 24 h. The mixture was then filtered, washed with acetone / water (99:1) (2 x 500 ml) and then allowed to suck dry on the 30 filter for 12 h. The solid was then dried in vacuo. Yield: 90%.

42 Example 9: Formation of building blocks via a Sonogashira reaction - 4-(4- [5- (acetylamino-methyl) -2-oxo-oxazolidin 3-yl] -2- fluoro-phenylethynyl } -4-hydroxy-piperidine- L carboxylic acid tert-butyl ester. S0 N O1 0 OO N N OH Wi F N H Step 1: 4-Bromo-3-Fluoro-phenyl)-carbamic acid benzyl ester. Sodium hydrogen carbonate (27.63 g, 0,329 mol, 1,25eg) and 10 a saturated solution of sodium hydrogen carbonate (333 ml) were added to a stirred solution of 4-bromo-3-fluoroaniline (50.0 g, 0,263 mol, leq) in acetone (660 ml) . The resulting mixture was cooled to 15*C and benzyl chloroformate (39 ml, 0.276 mo, 1,05eq) was added gradually, taking care that 15 the reaction temperature did not exceed 22 0 C. The mixture was stirred over 90 mins at room temperature and the acetone Was removed under vacuum. The aqueous layer was then extracted with ethyl acetate (3 x 150 ml) . The combined organic layers were then washed with a saturated 20 sodium chloride solution, and dried over MgSO 4 . Af -er filtration, the solvent was removed, and n-hexane added. The mixture was stirred during 30min at room temperature, the crys als were filtrated and washed with hexane to give the firs; crop of solid. The filtrate was evaporat d, and 25 the solid mixed with heptane at 0 0 C and stirred du ing 30min. T e product was again filtered, to give the second 43 crop of solid. The two crops were then combined, to give the product (85,3g, quantitative) as of solid. Step 2: (5R) 3-(4-Bromo-3-Fluoro-phenyl)-5-hydroxymethyl 5 oxazolidin-2-one Butyl lithium (2.3M in n-hexanes, 118,3 ml, 0,272 mol, 1,06eq) was added at -300C to anhydrous tert-butanol (25.0 g, 0,53 mol, 2,07eq) in anhydrous THF (170 ml), under nitrogen. The mixture was stirred for 30min at -300C, and 10 was then allowed to warm slowly to 0 0 C. After 30min at OC, the (4-bromo-3-fluoro-phenyl)-carbamic acid benzyl ester (83 g, 0,256 mol, leq) was added portionwise, keeping the temperature cold, and the mixture was stirred for an additional 30min at 00C. To this ice cold mixture, R(-) 15 glycidyl butyrate (39.7 ml, 0,288 mol, 1,12eq) were added and the mixture allowed to come gradually to room temperature. The mixture was extracted with saturated sodium chloride solution and the organic phase was dried over MgS04, filtrated and evaporated. The product was 20 obtained after recrystallisation of the crude product with ethyl acetate, to give (64,1g , 86.4%). Step 3: Methanesulfonic acid 3-(4-Bromo-3-Fluoro-phenyl)-2 25 oxo-oxazolidin-(5R)-ylemthyl ester. Methansulfonyl chloride (27.4 ml, 0,354 mol, 1.9 eg) was added to an ice-cold solution of the (5R) 3-(4-Bromo-3 Fluoro-phenyl)-5-hydroxymethyl oxazolidin-2-one (54.0 g, 0,186 mol, leq) and triethylamine (51.8 ml, 0,372 mel, 2eq) 30 in anhydrous DCM (420 ml) at 0CC. The resulting solution was allowed to come to room temperature, and then stirred over 3 hours. The mixture was then washed with 10% sodium hydrogen carbonate solution giving a precipitate. The solid 44 was filtered, The washed with DCM, and the filtrate and washings dried over MgSO 4 . After filtering, the solvent was removed, and the resulting solid was slurried with iethyl ether. The solid was then filtered, washed with ice cold 5 diethyl ether and dried to give the product (68,5 g quantitat ive) . Step 4: 5R)- Azidomethyl-3-(4-Bromo-3-Fluoro-phenyl) oxazolidin-2-one 10 A suspension of the Methanesulfonic acid 3-(4 -Bromo-3 Fluoro-phenyl) -2-oxo-oxazolidin- (SR) -ylemthyl est r (68.5 g, 0.186 mol,leq), tetrabutyl ammonium iodide (0.686 g, 0.00186 nol, O.01eq) and sodium azide (24.57g, 0 37B mol, 2.03eq) in anhydrous DMF (500 ml) was stirred 8 0 C under 15 nitrogen over night. The reaction was cooled, the DMF evaporated and the residue dissolved in ethyl acetate, washed with water and saturated sodium chloride .nd dried over MgS 4. After filtering, the filtrate was evaporated to give the product (58.6 g, quantitative) as a white solid. 20 Step 5: (5R) - Aminomethyl-3- (4-Bromo-3-Fluoro-phenyl) oxazolid n-2-one. A mixtu e of the (5R)- Azidomethyl-3-(4-Bromo -3-Fluaro phenyl) oxazolidin-2-one (10.5 g, 33.3 mmo,1 eq), 25 triphenylphosphine (12.6 g, 48 mmol, 1.44 eq) nd' iater (7.8 ml, 433 mmol, 13eq) in THF (180 ml) were stirred at 80C. Once the reaction was finished, it was cooled and then the solvents were removed under vacuum. The residue was purified by chromatography (ethyl acetate first to 30 remove :he triphenylphosphine derivatives and :hen with dichloremethane/methanol 9/1) to give the product (9.63 g, quantitative) as a white solid.

45 Step 6: (5S)-N-[(4-bromo-3-Fluoro-phenyl)-2-oxo-oxazolidin 5-ylmethyl]-acetamide To the (5R)- Aminomethyl-3-(4-Bromo-3-Fluoro-phenyl) oxazolidin-2-one (9.63 g , 33.3 mmol, leq) was added acetic 5 acid (9 ml, 156 mmol, 4.68eg) and acetic anhydride(9 ml, 95.3 mmol, 2.86eq). The suspension was stirred at room temperature for 1h and then the solvent was removed under high vacuum, to give the product (11.03 g, quantitative) as a beige solid. 10 Step 7: 4-oxo-piperidine-l-carboxylic acid tert-butyl ester. A solution of BOC 2 O (6.02 g, 27.6 mmol, 1.1 eq) in dioxane (25ml) was added to 4-Piperidone hydrochloride hydrate (3,9 15 g, 25.4 mmol, leq) in water/dioxane (50 ml, 1/1). The reaction was exothermic during the addition, and after the addition was finished the reaction was stirred for 4h at room temperature. The dioxane was evaporated and the resulting residue was extracted in ethyl acetate and then 20 dried over MgSO. After filtering, the filtrate was evaporated down to give the product (5.06 g, quantitative) as a white solid Step 8: 4-Hydroxy-4-trimethylsilanylethynyl piperidine-1 25 carboxylic acid tert-butyl ester. n-Butyl lithium (2.3M solution in n-hexanes, 16.0 ml, 36.8 mmol,1.1eq) was added to a solution of TMS-alkyne (6.03 ml, 42.4 mmol,1.26eq) in THF (124 ml) at - 78 0 C under nitrogen. The resulting mixture was stirred at -78 0 C for a further 30 30min, and then a solution of 4-oxo-piperidine-l-carboxylic acid tert-butyl ester (6.7 g, 33.6 mmol, leq) in THF (3OmL) was added at -78 0 C. The reaction mixture was stirred 15 minutes at 78 0 C, and then was allowed to warmed up 46 gradually to room temperature. After 30 min, adding 10% sodium hydrogen sulfate quenched the reaction. The two phases were separated and the aqueous layer was back extracted with ethyl acetate. The combined organic ayers 5 were washed with brine and dried over magnesium sulfate. After concentration, the pale yellow residue (7 g, '0%) was found pure enough to be carried on without further purification. 10 Step 9: 4-Ethynyl-4-Hydroxy-piperidine-l-carboxylic acid tert-butyl ester. A mixture of the 4-Hydroxy-4-trimethylsilanylethynyl piperidine-1- carboxylic acid tert-butyl ester (7 g, 23.5 mmolleq: and potassium carbonate (1.0 g, 7.25 mmol, 0.3eq) 15 in MeOH :30ml ) were stirred for 6 h at room temperature. After th:s time, the solvent was removed under reduced pressure and the residue suspended in diethyl ether. The suspension was washed with saturated ammonium chloride and water and dried over MgSO 4 . After filtering, the filtrate 20 was evaporated to give the product (4.5 g, 86%) as a white solid. Step 10: 4-(4-{Ss-(acetylamino-methyl)-2-oxo-oxazo idin-3 yl] -2-fl aoro-phenylethynyl) -4-hydroxy-piperidine-l 25 carboxyllc acid tert-butyl ester. PdCl2(P( 6 Hs) 3

)

2 (297 mg, 0.422 mmol, 0.1 eq) and 148mg of copper (1) iodide (160 mg, 0.78 mmol, 0.2 eq) were stirred at RT, under argon. Then the (5S)-N-[(4-bromo-3-Fluoro phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide (1. 0 g, 30 4.22 mmol, 1 eq), 4-Ethynyl-4-Hydroxy-piperidine-1 carboxylic acid tert-butyl ester (1.24 g, 5.5 mmol 1.3 eq) in anhydrous DMF (20 ml) and diisopropylamine (10 ml) were added. The mixture was stirred at RT during 30min. As the 47 reaction didn't start, the mixture was heated at S0 0 C during one night under stirring. Water and diethyl ether were added, the two layers separated, and the water layer was back extracted with diethyl ether. The combined 5 organic extracts were then washed with saturated sodium chloride solution and dried over MgSO 4 . After filtering, the filtrate was evaporated and the residue was purified by chromatography (first with ethyl acetate - in order to eliminate the triphenylphosphine residues and then with 10 Dichloromethane/MeOH) to give the product (1,55g, 77%) as a gray solid Example 20: Formation of building blocks via a Heck reaction 15 4-(3-{4-[5S-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2 fluoro-phenyl) -acryloyl) -piperazine-l-carboxylic acid tert butyl ester. 0 0 0 0O N N F NOO Hp 20 Step 1: Piperazine-1-carboxylic acid tert butyl ester A solution of 24g of di-tert-butyl dicarbonate (24 g, 0.11mol, leq) in 200ml dichloromethane (200ml) was added to a stirred solution of 20g piperazine (20 g, 0.23mol, 2eq) 25 in dichloromethane (800ml) at RT. The mixture was stirred overnight at RT and the mixture was then filtered and the filtrate was evaporated. Diethylether was then added to 48 the residue, and the mixture was filtered again, and to the filtrate n- heptane was added. The suspension was flitrated again anc the filtrate was evaporated to give the product (19 g, 42,9%) as a white solid. 5 Step 2: 4-Acryloyl-piperazine-1-carboxylic acid ter- butyl ester Acryloylchlorid (0.8 ml, 9.8 mmol, leq) was added dropwise to a stirred ice-cold solution of piperazine 1-carb xylic 10 acid tert butyl ester (2g, 9.8 mmol, leq) and trietaylamine (1,4ml, 9.8 mmol, leq) in dichloromethane (50 mL) at 0C. The mixture was then stirred and allowed to come to room temperature over 2 hours. IM Hydrochloric acid solution (50 mL) was Added to the mixture, and the two layers were 15 separated. The organic phase was washed with saturated sodium hydrogen carbonate solution (2 x 50 ml) and saturated sodium chloride solution (50 ml) and dried over MgSO 4 . After filtration, the solvent is evaporated. The residue was purified by chromatography (ethyl acetate/n 20 hexane 1 1) to give the product (1.26g, 49%) as a uhite solid. Step 3: 1-(3-{4-[5S- (acetylamino-methyl)-2-oxo-oxa2olidin 3-yl-2-Eluoro-phenyl}-acryloyl)-piperazine-1-carbcxylic 25 acid ter: butyl ester (5S)-N-[(4-bromo-3-Fluoro-phenyl)-2-oxo-oxazolidin-5 ylmethyll-acetamide (1.998 g, 6.0 mmol, 1 eq), 4-Acryloyl piperaziie-i-carboxylic acid tert butyl ester (1.6 g, 6.6 mmol, 1.- eq) triphenylphosphine (105 mg, 0.4 mmol, 0.067 30 eq), Palladium (II) acetate (134 mg, 0.6 mmol, 0.1 eq), diisopropylethylamine (10 ml),Potassium carbonate 829mg, 6 mmol, 1 aq)in DMF (15ml) were stirred at 1400C during 4 hours. Tae solvent was evaporated and the residue was 49 dissolved in dichloromethane, washed with water, dried over MgSO 4 and evaporated again. The residue was purified by chromatography (first with ethyl acetate - in order to eliminate the triphenylphosphine residues and then with 5 Dichloromethane/MeOH) to give the product (1,3g, 46%) as a grey solid Example 21: Formation of building blocks via epoxide ring opening with a phenol 10 4- (3-{4- [5S- (acetylamino-methyl) -2-oxo-oxazolidin-3-yl] -2 fluoro-phenoxy)-2-hydroxy-propionyl) -piperazine-l carboxylic acid tert butyl ester 0 0O~ K~ OH -\A 0 O N N \, N-/ F 0

N

H 15 Step 1: 4-Oxiranecarbonyl piperazine-1-carboxylic acid tert butyl ester A solution of anhydrous t-butyl hydroperoxide (5,5M in nonane, 2.07 ml, 11.3B mmol, 1,5eq) was added to anhydrous 20 THF (50 mL), at -780C under argon. To the resulting solution at -78 0 C was added butyl lithium (2,3M in n hexane, 3.36 ml, 8.4 mmol, 1.1 eq) was added and the solution is stirred for a further 5min at this temperature. A solution of the 4-Acryloyl-piperazine-l-carboxylic acid 25 tert butyl ester(1.96 g, 7.64 mmol, leg) in anhydrous THF (20 ml) was then added dropwise at -78 0 C. The resulting mixture was then allowed to warm slowly to room temperature and stirred for a further 16 hr. To the mixture was then 50 added sodium sulfite (1.5 g, 12 mmol, 1,55eq) and this was then stirred for 15min. The mixture was then diluted with diethylether (50ml), filtered through celite and the filtrate evaporated. The residue was purified by 5 chromatography (ethyl acetate/n-hexane 4/1) to give the product (0,39 g, 19%) as a white solid. Step 2: 4-(3-{4-[5S-(acetylamino-methyl)-2-oxo-oxazolidin 3-yll-2-fluoro-phenoxy}-2-hydroxy-propionyl)-piperaine-1 10 carboxylic acid tert butyl ester The 4-Oxiranecarbonyl piperazine-1-carboxylic acid :ert butyl ester (0.1 g, 0,39mmol, leq) was added to a s irred solution of N-[(5S)-(3- (3-fluoro-4-hydroxy-phenyl)} -2-oxo oxazolidin-5-ylmethyl]-acetamide (step 4, example 1 (0.104 15 g, 0,39m ol, leq) and K 2

CO

3 (0.081 g, 0,585mmol, 1,5eg) in DMF (2 m]). The mixture was heated to 80 0 C and then stirred for 4 hotra. This was then cooled down to room temp rature and then dichloromethane/methanol (10 ml, 9/1) addei. The organic layer was then washed with water (2 x 10 ml) and 20 saturated sodium chloride solution, and then dried over MgSO 4 . This was then filtered and the solvent is evaporated. The residue- was purified by chromatography (dichloromethane/methanol 9/1) to give the product (0.08 g, 39%) as A white solid. 25 Example 22: Formation of building blocks via alkylation of a phenol group 4-(2-{4- 5S-(acetylamino-methyl)-2-oxo-oxazolidin-3-yll-2 fluoro-phenoxy)-acetyl)-piperazine-1-carboxylic acid tert 30 butyl esier 51 0 O ON N0 N F HI 0 Step 1: 4- (2-bromo acetyl) -piperazine-1-carboxylic acid tert butyl ester 5 Bromo acetyl bromide (4.86 ml 1 , 21.47 mmol, leq) was added dropwise to a stirred ice cold mixture of the Piperazine-1 carboxylic acid tert butyl'ester (4.0 g, 21.47 mmol, leq) and diisopropyl ethyl amine (12.05 g, 92.5 mmol, 4,3eq) in dichloromethane (108 ml). The resulting mixture was washed 10 with water (2 x 50 mL) and saturated sodium chloride solution (100 mL) , and dried over MgSO 4 . After filtration, the solvent was evaporated and the residue was purified with chromatography with (ethyl acetate/n-hexane 1/1) to give the product (2,72g, 41%) as a orange oil. 15 Step 2: 4- (2-{4- [5S- (acetylamino-methyl) -2-oxo-oxazolidin 3-yll -2-fluoro-phenoxy}-acetyl) -piperazine-l-carboxylic acid tert butyl ester The 4-(2-bromo acetyl)-piperazine-l-carboxylic acid tert 20 butyl ester(2.0 g, 6.5 mmol, leg) was added to a stirred solution of N-[(SS) -(3-(3-fluoro-4-hydroxy-phenyl))-2-oxo oxazolidin-5-ylmethyll-acetamide (step 4, example 1) (1.75 g, 6.5 mmol, leg) and potassium carbonate (1.138 g, 9.75 mmol, 1,Seq) in DMF (32 ml) . The resulting mixture was 25 heated to 80 0 C and stirred for 30min, then cooled and dichloromethane/methanol (100 ml, 9/1) added. The organic layer was then washed with water (2 x 10 ml) and saturated 52 sodium chloride solution, and then dried over MgSO 4 . This was then filtered and the solvent is evaporated. The residue was purified by chromatography (dichlorcmethane/methanol 9/1) to give the product :1.72 g, 5 55%) as a brown solid. Example 23: Formation of building blocks via triple bond reduction 10 4- (2-{4- [5S-(acetylamino-methyl)-2-oxo-oxazolidin-3 -- yl] -2 fluoro-p enyl)-ethyl) -4-hydroxy-piperidine-l-carboxolic acid tert butyl ester 0 N AO 00 N N OH F N -0 H 15 101 Pd /C (100mg) was added a stirred solution of the 4-4 [5S- (acet ylamino-methyl) -2-oxo-oxazolidin-3-yl] -2-f uoro phenylet ynyl}-4-bydroxy-piperidine-1-carboxylic ac d tert butyl ester (example 19) (0.95 g, 2 mmol, leg) in 20 methanol/ethyl acetate (20'ml 1/l) . The mixture was then hydrogenated using a balloon of hydrogen. When th reaction went to completion, the 10% Pd/C was then emoved by filtration over celite and the solid then washed with methanol/ethyl acetate (2 x 10 ml 1/1). The filtra e and 25 washings were evaporated down to give a white solid (0.96 g, quantitative) that was found pure enough to be carried on witho t further purification.

53 General procedure for the removal of the t-butyl protecting groups Hydrogen chloride (1.25 M solution in methanol, 4,0 eg) was 5 added to the amine (leg) at room temperature. The mixture is either stirred at room temperature or heated at 40C until finished, cooled and then the pH was adjusted to pH1O using saturated sodium hydrogen carbonate solution. The resulting mixture was evaporated and dissolved again with 10 dichloromethane/methanol 9/1. The flask containing the mixture was then placed in an ultrasound bath, sonicated for 5 mins and then filtered. The filtrate was then evaporated to give the product that was then used without further purification, to couple to the quinolone moieties. 15 Example 24: 7-(4-(4-(SS-(acetylamino-methyl)-2-oxo oxazolidin-3-yl] -2-fluoro-phenylethynyl}-4-hydroxy piperidin-1-yl)-l-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro quinoline-3-carboxylic acid 0 0 F OH r"I I O N N 01 O O N NOH F N -0 20 H This was prepared by using the general deprotection method for the tert-butyl ester above to give the amine. The resulting amine was then coupled to the required 25 quinoline using the method described in example 5. This gave the required product in 8% yield over two steps.

54 Example 25: 7- (44- -[5S- (acetylamino-methyl) -2-oxo oxazolidin-3-yl]-2-fluoro-phenylethynyl)-4-hydroxy piperidin -1-yl) -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro 5 [1,81-napthyridine-3-carboxylic acid 0 0 F OH N N N 0 2O N OH V-I F This was prepared by using the general deprotection method for the tert-butyl ester above to give the amine. 10 The resulting amine was then coupled to the required quinoline using the method described in example 1 - step 7. This gave the required product in 15 % yield over two steps. 15 Example 2 5: 7-[4-(3-{4-[5S-(acetylamino-methyl)-2-o> o oxazolidi 2-3-yll -2-fluoro-phenyl}-acryloyl) -piperazi n-1--yl] -1-cyclop opyl-6-fluoro-4-oxo-1,4-dihydro-quinoline- 3 carboxyli acid 55 0 0 00 N F N F N-./ H C 0 N O HO This was prepared by using the general deprotection method for the tert-butyl ester above to give the amine. 5 The resulting amine was then coupled to the required quinoline using the method described in example 5. This gave the required product in 15% yield over two steps. Example 27: 7- [4- (3-(4- [5S-(acetylamino-methyl)--2-oxo 10 oxazolidin-3-yl] -2-f luoro-phenyl)-acryloyl) -piperazin-1-yl] -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro- [1, 81 napthyridine-3-carboxylic acid 0 0 00NN F N F N H N 0 N N 0 HO 15 56 This was prepared by using the general deprotection method for the tert-butyl ester above to give the aine. The resulting amine was then coupled to the require quinoline using the method described in example 1 - step 7. 5 This gave the required product in 11 % yield over two steps. Example 28: 7-[4-(3-{4 -[5-(acetylamino-methyl)-2-o o oxazolidin-3-yll -2-fluoro-phenoxy) -2-hydroxy-propionyl)-i 10 cyclopro yl-6-fluoro-4-oxo-1, 4-dihydro-quinoline-3 carboxylic acid F 00 O OHO(N N F/ OH 000NN Q\, N F 0 N-? H This was prepared by using the general deprote tion 15 method for the tert-butyl ester above to give the anine. The resulting amine was then coupled to the required quinolinE using the method described in example 5. This gave the required product in 5% yield over two steps. 20 Example :9: 7-[4-(3-(4-[5S-(acetylamino-methyl)-2-oo oxazolid:.n-3-yll -2-f luoro-phenoxy) -2-hydroxy-propionyl) -l cyclopropyl-6-fluoro-4-oxo-1,4-dihydro- [1,81 -napthyridine 3-carboxylic acid 57 F 0 O OH <N \ j OH 0 O N O a N N / O F 0 N H This was prepared by using the general deprotection method for the tert-butyl ester above to give the amine. The resulting amine was then coupled to the required 5 quinoline using the method described in example I - step 7. This gave the required product in 4 % yield over two steps. Example 30: 7-[4-(2-{4-[SS-(acetylamino-methyl)-2-oxo oxazolidin-3-yl] -2-f luoro-phenoxy) -acetyl) -piperazin-1-yl] 10 1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3 carboxylic acid O O 0 0O N \ -J NF F N H NO HO This was prepared by using the general deprotection 15 method for the tert-butyl ester above to give the amine. The resulting amine was then coupled to the required quinoline using the method described in example 5. This gave the required product in 20% yield over two steps.

58 Example 3L: 7-[4-(2-{4-[SS-(acetylamino-methyl)-2-O a oxazolidi a -3-yl] -2-fluoro-phenoxy) -acetyl) -piperazin-1-yl] 1-cyclopr >pyl-6-fluoro-4-oxo-1,4-dihydro- [1,8] napthyridine-3-carboxylic acid 00 00 NN \Wi F &4 NN HH N 0 1-0 5 This was prepared by using the general deprotection method fcr the tert-butyl ester above to give the amine. The resulting amine was then coupled to the required quinoline using the method described in example 1 - step 7. 10 This gave the required product in 18 % yield over two steps. Example 2: 7-[4-(2-(4-[5s-(acetylamino-methyl)-2-oo oxazolidi n-3-yl] -2-f luoro-phenyl} -ethyl) -4-hydroxy 15 piperidir -1-y1]-1-cyclopropyl-6-fluoro-4 -oxo-1, 4-diydro quinolinE -3-carboxylic acid 0 ( F A OH N N 0 0 0 N OH

F

59 This was prepared by using the general deprotection method for the tert-butyl ester above to give the amine. The resulting amine was then coupled to the required 5 quinoline using the method described in example 5. This gave the required product in 10% yield over two steps,

Claims (18)

1. Compounds of formula (I) Y / (CH2), \ O R ~ / \ A-Q N \C -- X / -C-Y (CH2)m X F N OH (I) R 5 wherein A is an alkylene group, an alkenylene group, an alkynylene group, a heteroalkylene group, a cycloalkylene group, a heterocycloalkylene group, an 10 arylene group or a heteroarylene group all of which groups may be substituted; Q is CR 4 or N; 15 X is CR 7 or N; Y is CR 6 or N; n is 1, 2 or 3; 20 m is 1, 2 or 3; R' is H, F, Cl, Br, I, OH, NH 2 , an alkyl group or a heteroalkyl group; 25 R2 is H, F or Cl; 61 R3 is H, an alkyl group, an alkenyl group, an alkynyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkylaryl group or a heteroarylalkyl group; 5 all of which groups may be substituted with one, two or more halogen atoms or amino groups; R' is hydroxy, a group of formula OPO 3 R2 or OS0 3 R 0 or a heteroalkyl group carrying at least one OH, NH 2 , S0 3 R' 0 , 10 PO 3 R2 or COON group or an ester of a naturally occurring amino acid or a derivative thereof, wherein the groups R 9 independently of each other are H, alkyl, cycloalkyl, aryl or aralkyl and wherein R 0 is H, alkyl, cycloalkyl, aryl or aralkyl; 15 R5 is selected from the following groups: RK(NNA- RK.Z A- RKN% 0 0 -N R R 6 is H, F, Cl or OMe; 20 R7 is H, F, Cl, OH, NH 2 , a substituted or unsubstituted alkyl group or a substituted or unsubstituted hetero alkyl group, or 25 R 3 and R 7 can be linked via an alkylene, an alkenylene or a heteroalkylene group or be a part of a cyclo alkylene or heterocycloalkylene group; in case R 3 is no H and R' is no H, F, OH, NH 2 or Cl; and 62 Ra is a CI 6 heteroalkyl, a heteroarylalkyl, a heteroalkylaryl or a heteroalkylheteroaryl group; 5 or a pharmacologically acceptable salt, solvate, hy drate or formulation thereof.

2. Compounds according to claim 1, wherein R' is H. 10

3. Compounds according to claim 1 or 2, wherein R2 is F or H.

4. Compounds according to any one. of claims 1 to 3, wherein R 3 is an ethyl, a 2-propyl, a C 3 -c 6 cycloalkyl, 15 a phenyl or a pyridyl group; all of which may be substituted with one, two, three or more fluorine atoms or amino groups.

5. Compounds according to any one of claims 1 to 4, 20 wherein R 3 is a cyclopropyl group.

6. Compounds according to any one of claims 1 to 3, wherein R 7 and R 3 together form a bridge of the formula -O-CH 2 -N(Me) - or -O-CH 2 -CH(Me--, wherein the preferred 25 stereochemistry at the chiral center is the one giving the (S) configuration in the final compound.

7. Compounds according to any one of claims 1 to 5, wherein R is H, F, Cl or a methoxy group which may be 30 substituted by one, two or three fluorine atoms,

8. Compounds according to any one of claims 1 to 5, wherein X is N or CH. 63

9. Compounds according to any one of claims 1 to 8, wherein R 4 is hydroxy or a group of formula OSO 3 H, OP0 3 H 2 , OCH 2 OPO2 3 H 2 , OCOCH 2 CH 2 COOH or an ester of a 5 naturally occurring amino acid or a derivative thereof.

10. Compounds according to any one of claims 1 to 9, wherein R' is a group of the formula -CH 2 NHCOCH=CHAryl 10 -CH 2 OHeteroaryl, -CH 2 NHSO 2 Me, -CH 2 NHCOOMe, -CH 2 NHCOMe, -CH2NHCS 2 Me, -CH 2 NHCSMe, -CH 2 NHCSNH 2 , -CH 2 NHCSOMe or -NHCOMe.

11. Compounds according to any one of claims 1 to 10, 15 wherein R 5 has the following structure: 0 N N H 0 0

12. Compounds according to any one of claims 1 to 11, wherein Y is CH or N. 20

13. Compounds according to any one of claims 1 to '2, wherein A is C 1 6 alkylene, C 2 -6 alkenylene, C 2 -6 alkynylene, C 16 heteroalkylene, cyclopropylene, epoxide, aziridine, thioepoxide, lactame or lac':one, 25 all of which groups may be subsitituted.

14. Compounds according to any one of claims 1 to 112, wherein A is a group of formula -CI2CH 2 -, -OCH2-, -OCH 2 CH 2 -, -SCH 2 -, -SCH 2 CH 2 -, -CH=CH-, -CaC-, 30 CH (OH) CH (OH) - or -CH(NH 2 )CH(OH)-. 64

15. A mono, di or tri sodium salt of a compound of formula (I) according to any one of claims 1 to 14, or mixtures thereof, especially a mono, di or tri sodium 5 salt of a compound of formula (I), wherein R 4 is OPO 3 H 2 or OS03H or mixtures thereof.

16. Pharmaceutical compositions containing a compound ac cording to any one of Claims I to -15 and optionally 10 carriers and/or adjuvants and/or diluents.

17. Pro-drugs, which contain a compound according to any one of Claims 1 to 16 and at least one pharmacologically acceptable protective group. 15

18. Use of a compound, a pharmaceutical composition or a pro-drug according to any one of Claims 1 to 17 for the manufacture of medicaments for the treatment of bacterial infections. MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE WATERMARK PATENT AND TRADE MARKS ATTORNEYS P27104AU01